Promega, JA2705, RANKL Bioassay

Measure Potency and Stability of Biologics Designed to Affect RANKL Signaling
Prequalified according to ICH guidelines
96- and 384-well plate formats
No primary cell culture required
Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Specifications：
RANKL Bioassay Cells (CPM) J310A 2 × 1ml
RANKL Bioassay Cells J312A 1 × 0.5ml
Fetal Bovine Serum J121A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
RANKL Bioassay Cells J312A 5 × 0.5ml
Fetal Bovine Serum J121A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
Receptor activator of nuclear factor-κB (RANK/TRANCE receptor/TNFRSF11A) is a member of the tumor necrosis factor receptor (TNFR) family. Binding of its ligand RANKL to the receptor regulates osteoclast formation, activation and survival in bone modeling and remodeling, along with several pathologic conditions characterized by increased bone turnover.
The RANKL Bioassay is a bioluminescent cell-based assay designed to measure RANKL stimulation or inhibition. The RANKL Bioassay Cells have been engineered to express luc2P in response to RANKL signaling. When RANKL binds, the receptor transduces intracellular signals, resulting in luminescence. The bioluminescent signal is detected and quantified using Bio-Glo™ Reagent.